Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.

Figg, W D; Sartor, O; Cooper, M R; Thibault, A; Bergan, R C; Dawson, N; Reed, E; Myers, C E

Figg, W D; Sartor, O; Cooper, M R; Thibault, A; Bergan, R C; Dawson, N; Reed, E; Myers, C E.

Affiliation

Figg WD; Pharmacology Branch, National Cancer Institute, Bethesda, Maryland, USA.

Am J Med ; 98(4): 412-4, 1995 Apr.

Article in En | MEDLINE | ID: mdl-7535978

Subject(s)

Androgens/agonists; Flutamide/pharmacology; Prostate-Specific Antigen/drug effects; Prostatic Neoplasms/immunology; Receptors, Androgen/drug effects; Aged; Flutamide/administration & dosage; Humans; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen/blood; Prostatic Neoplasms/drug therapy; Prostatic Neoplasms/metabolism; Prostatic Neoplasms/pathology; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Receptors, Androgen / Prostate-Specific Antigen / Flutamide / Androgens Limits: Aged / Humans / Male / Middle aged Language: En Journal: Am J Med Year: 1995 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links